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Liver ﬁbrosis is a worldwide clinical issue. Activation of hepatic stellate cells (HSCs) is the central
event during liver ﬁbrosis. We investigated the role of SATB1 in HSC activation and liver ﬁbrogenesis.
The results show that SATB1 expression is reduced during HSC activation. Additionally, SATB1
inhibits HSC activation, proliferation, migration, and collagen synthesis. Furthermore, CTGF, a
pro-ﬁbrotic agent, is also signiﬁcantly inhibited by SATB1 through the Ras/Raf-1/MEK/ERK/Ets-1
pathway. In vivo, SATB1 deactivates HSCs and attenuates ﬁbrosis in TAA-induced ﬁbrotic rat livers.
These data indicate that SATB1 plays an important role in HSC activation and liver ﬁbrosis.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Liver ﬁbrosis, a major cause of high morbidity and mortality
worldwide [1], is characterized by excessive and abnormal deposi-
tion of extracellular matrix (ECM), which leads to liver damage and
seriously threatens human health [2]. Therefore, a better under-
standing of the reversible steps in the ﬁbrotic response may lead
to identiﬁcation of new therapeutic targets.
Hepatic stellate cells (HSCs) play a central role in the develop-
ment of liver ﬁbrosis [3]. HSCs are in a quiescent state in normal
liver, and their main function is storing retinoids [4]. Aftercontinued liver damage, these quiescent HSCs transdifferentiate
into ﬁbrogenic, proliferative, and contractile myoﬁbroblast-like
phenotypes, as represented by the expression of a-SMA and by
the production of excessive collagen and by enhanced proliferation
and migration, thereby accelerating the progression of liver ﬁbrosis
[5,6]. Understanding the molecular mechanisms that drive this
phenotype switch may provide new insights into the pathogenesis
of liver ﬁbrosis.
In the special AT-rich binding protein 1 (SATB1), a nuclear
matrix attachment region binding protein, acted as a molecular
switch that could modulate gene expression by binding with
MARs [7–9]. Under physiological conditions, SATB1 is expressed
abundantly in thymocytes [8]. It is necessary during T-cell devel-
opment, orchestrating the spatial and temporal expression of mul-
tiple genes [10], and is involved in early Th2 cell differentiation
[11]. Since the seminal article on its role in breast cancer [12], a
large number of studies conducted in recent years have shown that
SATB1 abundantly expresses in various types of tumor and posi-
tively correlates with prognostic and clinico-pathological proper-
ties [12–14]. However, in colorectal cancer [15] and lung
squamous cell carcinoma [16], it is loss of expression rather than
overexpression of SATB1 that is associated with poor prognosis.
This supports the tissue-speciﬁc organizational role of SATB1.
Thus far, the role of SATB1 in HSCs and liver ﬁbrosis has remained
unknown.
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See Supplementary materials for detailed experimental materi-
als and methods.
2.1. Ethics statement
All animal works were performed in accordance with the
relevant national and international guidelines. The protocol was
approved by the Committee on the Ethics of Animal Experiments
of Tongji Medical College and monitored by the Department of
Experimental Animals of Tongji Medical College.
2.2. HSCs isolation and cell lines
The TAA-induced liver ﬁbrosis procedure was described previ-
ously [17]. Male Sprague–Dawley (SD) rats weighting approxi-
mately 250–270 g were purchased from the Department of
Experimental Animals of Tongji Medical College (Wuhan, China).
They were kept on a standard rat diet with free access to tap water
and food, with a 12-h light–dark cycle. Rats were randomly divided
into two groups, 3 each, injected intraperitoneally with either
thioacetamide (TAA; dissolved in saline, 200 mg/kg B.W.) twice a
week for up to 7 weeks or with the same amount of saline. Then
primary rat HSCs were isolated from these rats and were cultured
in DMEM/20% fetal bovine serum (FBS) containing penicillin and
streptomycin. The immortalized human hepatic stellate cell line
LX-2 [18] was cultured in DMEM/10% FBS.
2.3. SATB1-knockdown cells
Chemically synthesized siRNA directed against SATB1 were
transfected into the cells and the level of knockdown was
determined by real-time PCR and Western blot (Fig. S1).Fig. 1. SATB1 is downregulated in activated HSCs. Real-time PCR and Western blot were
from normal (N, n = 3) and ﬁbrosis (TAA, n = 3) rats and cultured for 3 days. The mRNA
⁄P < 0.05 vs. N. (B and E) Primary HSCs were isolated from normal rats and cultured for 7
n = 3. ⁄P < 0.05 vs. 1 d. (C and F) 2  105 freshly isolated rat HSCs were seeded in a 6-wel
PBS or TGF-b1 (10 ng/ml; PeproTech, NJ, USA) was added for 24 h. Levels of SATB1 a
mean ± S.E.M.2.4. SATB1 over-expressing cells
2.4.1. LX-2
The cells were transfected with pcDNA3.1()-SATB1 and
pcDNA3.1()-vector plasmids. Two single colonies of stable cells
with the highest SATB1 expression were used in this study
(Fig. S1).
2.4.2. Rat HSCs
Adenoviral vectors expressing rat SATB1 and the negative con-
trol (AdGFP) were purchased from Obio Technology Co., Ltd.
(Shanghai, China). Cultured rat HSCs were infected with AdSATB1
or AdGFP at a multiplicity of infection (MOI) of 100 (Fig. S1).
2.5. Animal ﬁbrosis models and adenoviral delivery in vivo
Male SD rats weighting about 200 g were randomly divided into
four groups, 7 each. TAA was injected intraperitoneally (200 mg/kg,
twice a week for 6 weeks) to all groups of rats (group II, III, and IV)
except for one group, which were injected intraperitoneally with
the same amount of saline (group I). From the beginning of the
6th week, rats were infused with PBS (group I and II), 5  109 pfu
AdGFP (group III), or AdSATB1 (group IV) via the tail vein twice a
week for 2 weeks. At the ending of the 7th week, all of the rats
were sacriﬁced and liver samples were collected (Fig. S6C). RNA
and protein were extracted directly as soon as possible. Liver tis-
sues were ﬁxed in 4% buffered paraformaldehyde and then embed-
ded in parafﬁn for immunohistochemistry analysis.
2.6. Raf-1 membrane translocation and Ras activation assay
The membrane protein was extracted by using the Membrane
and Cytosol Protein Extraction Kit (Thermo Fisher scientiﬁc, MA,
USA). The cytosolic and membrane fraction were immunoblottedused to assess gene expression in rat HSCs. (A and D) Primary HSCs were isolated
levels of SATB1 (A) and the protein levels of a-SMA and SATB1 (D) was analyzed.
days. The expression of a-SMA and SATB1 in culture-activated HSCs were assessed.
l-plate well. The next day cells were cultured in serum-free medium for 48 h. Then,
nd a-SMA expression were measured. n = 3. ⁄P < 0.05 vs. PBS. Data are shown as
Fig. 2. SATB1 inhibits the activation of LX-2 cells. (A) The expression of a-SMA was measured by immunoﬂuorescence after SATB1 expression was silenced or enhanced in LX-
2. (B and C) Genes involved in ﬁbrogenesis (a-SMA, CTGF, COL1A1, and COL3A1) were analyzed by real-time PCR (B) andWestern blot (C) after SATB1 expression was silenced
in LX-2. n = 3. ⁄P < 0.05 vs. NC. (D and E) Genes were analyzed by real-time PCR (D) and Western blot (E) after SATB1 expression was enhanced in LX-2. n = 3. ⁄P < 0.05 vs. Vec.
Data are shown as mean ± S.E.M.
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Ras Activation Assay Kit (Millipore) according to the manufac-
turer’s protocol.
2.7. Statistical analysis
Results are presented as mean ± S.E.M. from three independent
experiments. The analysis of Student’s t-test and ANOVA/tukey
post hoc test for comparison of normally distributed data between
paired data and among the groups respectively. Data not normally
distributed were compared using the Mann–Whitney tests. A P-
value <0.05 was considered statistically signiﬁcant.
3. Results
3.1. SATB1 shows an inverse relationship with HSCs activation
To study the expression and distribution of SATB1 in liver tis-
sues, immunohistochemistry was performed on histological sec-
tions of rat liver tissues. Positive staining of SATB1 was seen only
in the nucleus of liver non-parenchymal cells, almost no staining
was observed in the hepatocytes (Fig. S3A). In addition, SATB1was expressed in rat primary HSCs and was mainly located within
the nucleus (Fig. S3B).
To explore the relationship between SATB1 expression and
HSCs activation, HSCs were isolated from both the normal and
TAA rats (n = 3 rats/group). The HSCs were cultured for 3 days
and then the expression of SATB1 and a-SMA (a well-established
marker of activated HSCs) were measured. Compared with normal
rats, lower expression of SATB1 along with higher expression of a-
SMA was found in HSCs isolated from TAA rats (Fig. 1A and D).
Similar results were also observed in two models of in vitro
activation of rat HSCs. When rat HSCs were freshly isolated, they
were in a quiescent state [4] and then were activated by culture
[5]. In our study, they were freshly isolated and cultured for up
to 7 days (Fig. S2). The expression of a-SMA was increased, while
SATB1 expression dramatically decreased (Fig. 1B and E).
Additionally, we treated rat HSCs with TGF-b1, as TGF-b1 was
the strongest stimulator for HSCs activation (Fig. 1C and F) [19].
As expected, TGF-b1 signiﬁcantly induced increased a-SMA
expression compared with the untreated group, while SATB1
expression was inhibited. Taken together, these results indicate
that there was a strong negative correlation between SATB1
expression and HSCs activation.
Fig. 3. SATB1 inhibits the proliferation and migration of LX-2 cells. (A and C) The cell proliferation rates were measured by a CCK-8 cell proliferation assay kit after SATB1
expression was silenced or enhanced in LX-2. Absorbance at 450 nm was determined at the indicated time points. n = 3. ⁄P < 0.05 vs. NC or Vec. (B and D) The mRNA
expression of cyclin E1 was analyzed by real-time PCR. n = 3. ⁄P < 0.05 vs. NC or Vec. (E and F) The migration rates of LX-2 cells were measured after SATB1 expression was
silenced or enhanced by transwell migration assays. The number of migrated cells were counted in eight random ﬁelds. n = 3. ⁄P < 0.05 vs. NC or Vec. Data are shown as
mean ± S.E.M.
1362 J. He et al. / FEBS Letters 589 (2015) 1359–13683.2. SATB1 inhibits the activation of HSCs in vitro
Next, we investigated whether SATB1 was involved in the pro-
cess of HSCs activation. We ﬁrst delivered siRNA against SATB1
into LX-2 (siSATB1-1 or siSATB1-2). As activated HSCs exhibited
[20], knockdown of SATB1 resulted in a signiﬁcant increase in
the expression of a-SMA (Fig. 2A). In the meantime, other ﬁbro-
sis-related genes, including CTGF, COL1A1, and COL3A1 were also
upregulated (Fig. 2B and C). Furthermore, we established SATB1-
overexpressing cells. As expected, upregulation of SATB1 resulted
in deactivation of LX-2 cells, as the expression of a-SMAwas signif-
icantly reduced (Fig. 2A). The levels of CTGF, COL1A1, and COL3A1
were also decreased (Fig. 2D and E). Similar results were observed
in rat HSCs, except that the expression of COL3A1 did not changesigniﬁcantly in rat HSCs treated with AdSATB1 (Fig. S4). These ﬁnd-
ings suggest that SATB1 could inhibit HSCs activation and collagen
synthesis.
3.3. SATB1 inhibits the proliferation and migration of HSCs in vitro
Previous research demonstrated that activated HSCs have the
ability to proliferate and migrate into the site of injury, which con-
tributes to the progression of liver ﬁbrosis [21]. Therefore, cell pro-
liferation and migration were analyzed. Compared to NC, LX-2 cells
transfected with siSATB1 (siSATB1-1 or siSATB1-2) had a greater
proliferative capacity and higher absorbance value (Fig. 3A). On
the other hand, upregulation of SATB1 signiﬁcantly suppressed
proliferation of LX-2 cells (Fig. 3C). Furthermore, real-time PCR
Fig. 4. SATB1-dependent downregulation of CTGF involved MEK/ERK/Ets-1. (A and B) After SATB1 expression was silenced or enhanced in LX-2 cells, p-Ets-1, t-Ets-1, p-ERK,
t-ERK, p-MEK, t-MEK, and GAPDH expression were assessed by Western blot. n = 3. ⁄P < 0.05 vs. NC or Vec. (C) Western blot analysis of the protein level of CTGF with siRNA
inhibition of Ets-1. n = 3. ⁄P < 0.05 vs. siSATB1-1() + siEts-1(); &P < 0.05 vs. siSATB1-1(+) + siEts-1(). (D and E) The LX-2 cells were transfected with NC or siSATB1-1. After
culture for 24 h, the cells were treated with U0126 (10 lM) and PD98059 (30 lM) for 24 h. The expression of CTGF, p-ERK, and t-ERK were measured by Western blot. n = 3.
⁄P < 0.05 vs. NC + DMSO; &P < 0.05 vs. SATB1 + DMSO. Data are shown as mean ± S.E.M.
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of the G1-S transition promoter cyclin E1 (Fig. 3B and D). The
results indicate that SATB1 may suppress HSCs proliferation by
downregulating cyclin E1 expression. The migration ability signif-
icantly increased after SATB1 silencing compared with NC, and
more cells migrated through the pores (Fig. 3E); inversely, the
migration capability was inhibited after enhanced expression of
SATB1 (Fig. 3F).
3.4. SATB1 inhibits CTGF expression through the MAPK pathway
Emerging evidence has remarkably established the important
role of CTGF in driving the activated phenotype in HSCs [22].
Stimulation of HSCs with CTGF caused an acceleration of a pattern
of gene expression that involved in HSCs activation, proliferation,
migration, and collagen production [23–25]. Therefore, we investi-
gated the molecular mechanism of the regulation of CTGF expres-
sion by SATB1 next.
3.4.1. SATB1-dependent downregulation of CTGF involves Ets-1
inhibition
Two transcriptional factors, Smad and Ets-1, are known as
essential players that regulate CTGF expression [26,27].
Therefore, we analyzed the regulatory effect of SATB1 on the tran-
scriptional activity of Smad and Ets-1. Our results revealed that
SATB1 had no effect on the expression of Smad2/3/4/7 in LX-2 cells(Fig. S5A). At the same time, Smad3 phosphorylation and Smad4
nuclear translocation were also unchanged (Fig. S5B). After
SATB1 expression was silenced, surprisingly, the level of phos-
pho-Ets-1 (Thr38) and its accumulation in the nucleus was signif-
icantly elevated, while the total Ets-1 expression was nearly
unchanged; inversely, the level of phospho-Ets-1 signiﬁcantly
decreased when SATB1 expression was enhanced
(Figs. 4A, B and 5G, H). In addition, we used Ets-1 siRNA in
SATB1-knockdown cells. The results showed that inhibition of
Ets-1 antagonized the elevation of CTGF expression in SATB1-
knockdown cells (Fig. 4C). Considered together, these results sug-
gest that Ets-1 activation is involved in the regulation of CTGF
expression by SATB1.
3.4.2. SATB1-dependent downregulation of CTGF involves MEK/ERK
inhibition
Previous works demonstrated that the activation of Ets-1
requires its phophorylation by upstream MAPKs, including p38,
MEK/ERK, and JNK [28,29]. So we next tested which MAPK was tar-
geted by SATB1-mediated Ets-1 inhibition. The results show that
SATB1 failed to activate p38 and JNK activity (Fig. S5C and D).
Remarkably, knocking down of SATB1 resulted in an increase in
the phosphorylation of MEK and ERK; and upregulation of SATB1
signiﬁcantly reduced the phosphorylation of MEK and ERK
(Fig. 4A and B). Additionally, we used MEK1/2 inhibitors U0126
and PD98059 in SATB1-knockdown cells. Consistent with the
Fig. 5. SATB1-dependent downregulation of CTGF involved Ras/Raf-1/MEK/ERK/Ets-1. After SATB1 expression was silenced or enhanced in LX-2 cells, (A and B) lysates
corresponding to cytosolic and membrane fractions were assessed by western blot. ATP1A1 and GAPDH were used as as a loading control. n = 3. ⁄P < 0.05 vs. NC or Vec; (C and
D) cells were lysated for the Ras activity assay. Total Ras was used as a loading control. n = 3. ⁄P < 0.05 vs. NC or Vec. (E and F) The LX-2 cells were transfected with NC or
siSATB1-1. After culture for 24 h, the cells were treated with GW5074 (10 lM) and manumycin A (3 lM) for 24 h. The expression of CTGF, p-ERK, t-ERK, p-MEK, t-MEK, and
GAPDH were measured by Western blot. n = 3. ⁄P < 0.05 vs. NC + DMSO; &P < 0.05 vs. SATB1 + DMSO. (G and H) The LX-2 cells were transfected with NC or siSATB1-1. After
culture for 24 h, the cells were treated with U0126, PD98059, GW5074, and manumycin A for 24 h. The expression of p-Ets-1 and t-Ets-1 were measured by Western blot (G)
and immunoﬂuorescent staining of p-Ets-1 was assayed by confocal microscopy (H). Data are shown as mean ± S.E.M.
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Fig. 6. SATB1 ameliorates TAA-induced rat liver ﬁbrosis. (A) Liver ﬁbrosis was assessed by H&E staining (40), Masson’s trichrome staining (40), and Sirius Red staining
(100). (B and C) Semiquantitative analysis of the Masson’s trichrome (B) and Sirius Red staining (C). n = 7. ⁄P < 0.05 vs. AdGFP. (D) The content of hydroxyproline. n = 7.
⁄P < 0.05 vs. AdGFP. Data are shown as mean ± S.E.M.
Table 1
SATB1 improves hepatic serum biochemical parameters.
Group ALB (g/L) ALT (U/L) AST (U/L)
Normal 35.9 ± 3.6 42.9 ± 6.5 89.8 ± 10.2
PBS 13.5 ± 3.6 220.1 ± 12.6 276.2 ± 23.1
AdGFP 15.8 ± 3.5 240.4 ± 15.8 280.8 ± 16.9
AdSATB1 27.4 ± 4.2* 148.8 ± 8.9* 164.6 ± 11.4*
Normal means rats without treatment.
* P < 0.05 vs. PBS or AdGFP group.
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vation of CTGF expression was greatly reduced by treatment with
the MEK inhibitors (Fig. 4D and E). At the same time, elevation of
the phosphorylation of ERK and Ets-1 caused by knockdown of
SATB1 was noticeably reduced (Figs. 4D, E, and 5G); the nuclear
level of phospho-Ets-1 was also reduced (Fig. 5H). These results
imply that inhibition of CTGF by SATB1 may result from a blockade
of the MEK/ERK/Ets-1 cascade.
3.4.3. SATB1-dependent downregulation of CTGF involves Ras/Raf-1
inhibition
MEK/ERK activation is frequently a result of Ras activation,
which recruits the Raf-1 to the plasma membrane, and in turn acti-
vates MEK and ERK [30]. As shown in Fig. 5A, Raf-1 was clearlyenriched in membrane fractions in LX-2 cells after SATB1 was
silenced as compared with NC. Consistent with this, Ras activity
remarkably increased (Fig. 5C). On the contrary, upregulation of
SATB1 inhibited the membrane translocation of Raf-1 when com-
pared with the vector control cells (Fig. 5B). In the meantime, the
activity of Ras was inhibited (Fig. 5D). A Raf-1 inhibitor
(GW5074) and a Ras inhibitor (manumycin A) were used, and both
of them effectively reversed the increased levels of CTGF in LX-2-
siSATB1 cells (Fig. 5E and F). Furthermore, the elevation of MEK
and ERK phosphorylation and the nuclear level of phospho-Ets-1
caused by the knock down of SATB1 was noticeably reduced by
treatment with GW5074 and manumycin A (Fig. 5E–H). All in all,
these results suggest that the Ras-Raf-1-MEK-ERK-Ets-1 signaling
pathway is involved in SATB1-induced CTGF downregulation in
LX-2 cells.
3.5. SATB1 inhibits TAA-induced rat-liver ﬁbrosis
Finally, we assessed the role of SATB1 in vivo by using the rat
model of TAA-induced liver ﬁbrosis. In our pilot study, the efﬁcacy
of AdSATB1 delivery to the rat liver was assessed. The SATB1mRNA
and protein began to express at day 1 and peaked at day 3 after
being injected with AdSATB1 and then declined when compared
with AdGFP injection (Fig. S6A and B). Thus, a tail-vein injection
was given twice a week to maintain consistent SATB1 expression.
Fig. 7. SATB1 reduces the activation of HSCs in vivo. (A) Immunohistochemistry was used to determine the expression of a-SMA (100), CTGF (100) and COL1A1 (100).
(B)–(D) Real-time PCR was used to detect the expression of a-SMA (B), CTGF (C), and COL1A1 (D) in rat liver tissues. n = 7. ⁄P < 0.05 vs. AdGFP. (E) Western bolt was used to
detect the protein level of a-SMA, CTGF, and COL1A1 in rat liver tissues. n = 7. ⁄P < 0.05 vs. AdGFP. Data are shown as mean ± S.E.M.
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opment of liver ﬁbrosis as conﬁrmed by H&E, Masson’s trichrome,
and Sirius Red staining, compared with AdGFP injection (Fig. 6A–
C). Meanwhile, a quantitative analysis revealed signiﬁcantly lower
hydroxyproline content in rats receiving AdSATB1 (Fig. 6D). In
addition, AdSATB1 administration signiﬁcantly improved hepatic
serum biochemical parameters (Table 1). In line with the in vitro
results, the data indicated that, following AdSATB1 treatment, the
expression of a-SMA, CTGF, and COL1A1 decreased when com-
pared with AdGFP group (Fig. 7). These genes were mainlyproducing by activated HSCs [31], which indicated that SATB1
may inhibit HSCs activation in vivo.
4. Discussion
Our results showed that the expression of SATB1 was detected
in liver non-parenchymal cells but not hepatocytes in normal liver
tissues. It is consistent with previous studies that the expression of
SATB1 could be detected in liver tumor samples but hardly
detected in healthy liver tissues [32]. Besides, SATB1 expression
Fig. 8. Schematic diagram of the signaling pathways involved in inhibition of CTGF
expression by SATB1 in LX-2 cells. SATB1 inhibits CTGF expression by inactivation
of Ras, Raf-1, MEK, ERK, and Ets-1, which suppresses DNA biding activity of Ets-1 to
the Ets-1 site, resulting in transcriptional repression of CTGF expression.
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escent phenotype and after their activation in vivo (isolated from
rats with TAA-induced ﬁbrosis) and in vitro (cultured on plastic
for 7 days or treated with TGF-b1). The present data demonstrated
a decrease in SATB1 expression using all of these methods for HSCs
activation.
Next, we investigated the role of SATB1 on HSCs activation. Our
results reveal that SATB1 dramatically inhibits expression of ﬁbro-
sis-related genes (a-SMA, CTGF, and COL1A1) in LX-2 and rat HSCs,
providing evidence that SATB1 negatively regulates HSCs activa-
tion and collagen synthesis. Moreover, SATB1 inhibits LX-2 cells
proliferation and cyclin E1 expression. Additionally, the migration
of LX-2 cells is also inhibited by SATB1. These ﬁndings imply that
SATB1 can inhibit the process of HSCs activation.
CTGF, an important pro-ﬁbrotic mediator, is mainly produced
from activated HSCs and plays an important role in HSCs activation
and liver ﬁbrosis [22,24,25,33]. Previous studies reported that
SATB1 modulated numerous genes involved in TGF-b, Wnt, and
MAPK signaling pathways [34]. Therefore, we sought to investigate
which signaling pathway was involved in the inhibition of CTGF
expression by SATB1. It has been reported that there are many
transcription factor-binding sites including Smad, AP-1, NF-jB,
and Ets-1 in the promoter region of the CTGF gene [35–37]; and
CTGF expression is modulated in Smad-dependent and Smad-inde-
pendent pathways [38–40]. Our results showed that SATB1 had no
effect on the Smad pathway in LX-2 cells. Surprisingly, SATB1
inhibited the phosphorylation of Ets-1 and its nuclear accumula-
tion. Moreover, Ets-1 siRNA could attenuate elevation of CTGF
expression caused by knock down of SATB1. The results were in
line with previous studies that found that phosphorylation of
Thr38 on Ets-1 was associated with increased transcriptional activ-
ity; increased transcriptional activity of Ets-1 leaded to expressionof target genes, including CTGF [41–43]. Numerous studies have
also suggested that Ets-1 transcription and activation are induced
by upstream kinases MAPKs, including P38, MEK/ERK, and JNK
[28,29,44]. Our research showed that SATB1 signiﬁcantly inhibited
the phosphorylation of ERK1/2 and its upstream MEK1/2.
Furthermore, the activation of Ets-1 and subsequent induction of
CTGF expression caused by knock down of SATB1 were inhibited
by MEK1/2 inhibitors (U0126 and PD98059). These results indicate
that SATB1 might inhibit MEK/ERK/Ets-1 pathway to repress CTGF
expression.
Ras proteins, a member of the superfamily of small GTPase,
recruited Raf-1 to the membrane through activation of the Ras
molecules via the GTP/GDP exchange, and subsequently activated
MEK and ERK [30,45]. In pancreatic cancer cells, activation of the
Ras/MEK/ERK pathway was required for CTGF induction [46]. Our
study found that SATB1 signiﬁcantly inhibited activation of Ras
and membrane translocation of Raf-1. Furthermore, treatment of
SATB1-knockdown cells with manumycin A (a Ras inhibitor) and
GW5074 (a Raf-1 inhibitor) attenuated elevation of CTGF expres-
sion, as well as the phosphorylation of MEK, ERK, and Ets-1.
These results showed that the Ras/Raf-1/MEK/ERK/Ets-1 signaling
pathway participated in the inhibition of CTGF expression by
SATB1 (Fig. 8).
Eventually, animal experiments were carried out to prove the
effect of SATB1 in vivo. Consistent with the in vitro data, aden-
ovirus-mediated SATB1 administration signiﬁcantly attenuated
ECM deposition and improved liver function compared with
AdGFP or PBS injection. Additionally, the expression of a-SMA,
CTGF, and COL1A1 were also decreased after AdSATB1 injection.
These genes were mainly produced by activated HSCs [31], which
indicated that SATB1 may attenuate liver ﬁbrosis through deacti-
vating HSCs.
However, contrasting results have been found in some cancer
cell lines, where SATB1 overexpression promotes CTGF expression,
cell proliferation and migration [12–14]. Notably, the different
roles of SATB1 in different cell types have been reported. A recent
study revealed that SATB1 had an opposite effect on cell prolifera-
tion between mouse embryonic ﬁbroblasts (MEFs) and tumor cells
[47]. Coincidentally, different responses to SATB1 overexpression
by the different MCF10A cell lines was attributed to their disparate
gene expression patterns [48]. One potential interpretation is that
the genetic makeup of cells critically determines the function of
SATB1. Anyway, the molecular and cellular mechanism underlying
such events requires further investigation.
In conclusion, the data reported in this study have shown for
the ﬁrst time to our knowledge that SATB1 was involved in the reg-
ulation of HSCs activation and liver ﬁbrosis. SATB1 expression neg-
atively correlated with HSCs activation and, in addition, inhibited
HSCs activation, proliferation, and migration. Additionally, the
CTGF expression was inhibited by SATB1 through the Ras/Raf-1/
MEK/ERK/Ets-1 pathway in LX-2 cells. Furthermore, the in vivo
study showed that adenovirus-mediated SATB1 injection can efﬁ-
caciously inhibit HSCs activation and attenuate rat-liver ﬁbrosis
and improve liver function. Collectively, the evidence points to
the important role of SATB1 in HSCs activation and ﬁbrosis.
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